BioDelivery Sciences International
(NASDAQ: BDSI)
4.61
-0.05
-1.07%
-0.05
-1.07%
MORE ON BDSI
COMPANY INFORMATION
| Exchange: | NASDAQ national market |
| Stock: | BioDelivery Sciences International, Inc. |
| Industry: | Biotechnology |
| Employees: | 21 |
DESCRIPTION
| BioDelivery Sciences International, Inc., was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company is a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new formulations of proven therapeutics. Utilizing its drug delivery technologies, it is developing formulations of pharmaceuticals aimed mainly at acute conditions occurring in patients, mostly notably in the areas of pain and fungal infections. In formulating its products and product candidates, it utilizes the novel, patent protected and proprietary BioErodible MucoAdhesive (“BEMA®”) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). Its first U.S. Food and Drug Administration approved product, ONSOLIS®, as well as its pipeline of product candidates; utilize its BEMA® technology. On July 16, 2009, the Company announced the U.S. approval of its first product, ONSOLIS®. It is indicated for the treatment of breakthrough pain (i.e., pain that “breaks through” the effects of other medications being used to control persistent pain) in opioid tolerant patients with cancer. Its next product, currently in development, is BEMA® Buprenorphine, a potential treatment for moderate to severe chronic pain. Its BioErodible MucoAdhesive (known as BEMA®) drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). BEMA® films have the capability to deliver a rapid, reliable dose of drug across the buccal mucosa for time-critical conditions such as “breakthrough” cancer pain or in situations where gastrointestinal absorption of an oral drug is not practical or reliable, such as nausea and vomiting. The Company is subject to regulation for safety, efficacy and quality by governmental authorities in the United States and other countries. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The major averages continue to hover near their lows with the S&P 500 off by 0.2%. Yesterday's top performer, the industrial sector, is among the early laggards today as defense companies lag. General Electric (GE 24.15, -0.18) trades
...
More
MORE MARKET NEWS
Sponsored by: